- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06304350
Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
March 11, 2024 updated by: Jiang Fan, Tongji University
A Single Arm, Single Center, Phase II Clinical Study of Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
This study is a prospective, single center, open label, single arm clinical study.
Select resectable locally advanced (cT3-4aN0M0, cT1-3N1-2M0, cII/III stage) esophageal cancer with pathological diagnosis of squamous cell carcinoma for inclusion, receive pembrolizumab combined with platinum containing dual drug (albumin paclitaxel+carboplatin) treatment for 2 courses, and undergo surgery.
After surgery, continue pembrolizumab immunotherapy.
Using pCR as the main endpoint of the study
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, single center, open label, single arm Phase II clinical study.
Patients with locally resectable advanced esophageal squamous cell carcinoma were selected for inclusion in the study, who received a 2-course neoadjuvant treatment with pembrolizumab combined with platinum containing dual drugs.
After evaluation, surgery was performed.
The efficacy and safety of pembrolizumab combined with chemotherapy neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma were observed, with pCR and MPR as the main research endpoints.
Study Type
Interventional
Enrollment (Estimated)
25
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jiang Fan, MD
- Phone Number: 15901013210
- Email: fan_jiang@tongji.edu.cn
Study Contact Backup
- Name: Fu Yang, DM
- Phone Number: 18101839885
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Recruiting
- Shanghai General Hospital
-
Principal Investigator:
- Jiang Fan, MD
-
Contact:
- Jiang Fan, MD
- Phone Number: 02163240090
- Email: fan_jiang@tongji.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Baseline stage resectable cII/III esophageal squamous cell carcinoma (8th UICC TNM stage);
- Failure to receive anti-tumor treatment for esophageal squamous cell carcinoma;
- Age range from 18 to 75 years old;
- There are no surgical contraindications in the preoperative evaluation of various organ functions;
- The following laboratory tests confirm that the bone marrow, liver and kidney functions meet the requirements for participating in the study: hemoglobin ≥ 9.0g/L; White blood cell count 4.0-10 × 109/L; Neutrophil absolute value (ANC) ≥ 1.5 × 109/L; Platelet count ≥ 100 × 109/L; Total bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST ≤ 2.5 times the upper limit of normal values; The international standardized ratio of prothrombin time is ≤ 1.5 times the upper limit of normal values, and some prothrombin time is within the normal range; Creatinine ≤ 1.5 times the upper limit of normal value;
- Patients who have not undergone chemotherapy, radiation therapy, or hormone therapy for malignant tumors, have no history of other malignant tumors, and do not include prostate cancer patients who have received hormone therapy and have obtained DFS for more than 5 years;
- Expected to achieve R0 resection;
- Physical state ECOG 0-1;
- The subjects must understand and sign the informed consent form
Exclusion Criteria:
- Individuals who have received previous treatment for esophageal cancer (surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc.);
- Not suitable for surgery or with surgical contraindications;
- Have a history of other anti PD-L1/PD-1 treatments;
- Individuals with immunodeficiency or long-term systemic steroid therapy, or those who have received any immunosuppressive therapy within 7 days prior to receiving the study drug;
- Individuals with active autoimmune diseases requiring systemic treatment within 2 years;
- Patients with poor control of heart disease
- Pregnant or lactating female patients;
- For patients with drug allergies in the protocol.
Exit criteria:
Withdrawal cases refer to subjects who have stopped continuing treatment in clinical research due to various reasons. Subjects who experience the following situations will withdraw from the investigational treatment:
- The main indicators are missing, and more than half of the items that can be filled in CRF are missing;
- The surgical procedure violates the plan;
- Cases that are excluded due to adverse reactions are not evaluated for efficacy, but side effects should be included in the statistics;
- According to the researcher's opinion, continuing to participate in the study will be harmful to their health;
- Patients who fail to undergo non-surgical treatment due to various reasons, including malignant tumor progression, underlying disease progression, patient or their trustee requesting withdrawal, will be reported together;
- Missing subjects. All subjects who withdrew from the study should record their reasons for withdrawal in the CRF and their medical records. According to the ITT principle, all withdrawn cases should undergo survival analysis and toxicity evaluation for the corresponding group.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination of pembrolizumab and platinum containing dual drugs
After 2 courses of treatment with pembrolizumab combined with platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed, and postoperative pembrolizumab immunomaintenance therapy continued
|
After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab immunomaintenance therapy continued after surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological complete remission (pCR)
Time Frame: in two weeks after the surgical resection
|
Defined as the absence of any residual esophageal squamous cell carcinoma cells, including the primary lesion and lymph nodes
|
in two weeks after the surgical resection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major pathological remission (MPR)
Time Frame: in two weeks after the surgical resection
|
The primary pathological response (MPR) is defined as residual survival tumor during surgery ≤ 10%.
|
in two weeks after the surgical resection
|
R0 resection rate
Time Frame: in two weeks after the surgical resection
|
in two weeks after the surgical resection
|
|
Progression free survival (PFS)
Time Frame: receiving therapy,up to approximately 2years.
|
receiving therapy,up to approximately 2years.
|
|
Total survival time (OS)
Time Frame: The time from the patient's randomization receiving therapy to death from any cause,up to approximately 2years
|
The time from the patient's randomization receiving therapy to death from any cause,up to approximately 2years
|
|
Safety (incidence of adverse drug reactions)
Time Frame: Randomly group patients to receive treatment for up to two years
|
Randomly group patients to receive treatment for up to two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 17, 2024
Primary Completion (Estimated)
February 25, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
February 21, 2024
First Submitted That Met QC Criteria
March 4, 2024
First Posted (Actual)
March 12, 2024
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 11, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- SGHDOT-24-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
National Cancer Institute (NCI)NRG OncologyCompletedEsophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7United States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer NosGermany
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0China
-
University of Wisconsin, MadisonActive, not recruitingResectable Esophageal Cancer | GastroEsophageal CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
-
Tianjin Medical University Cancer Institute and...The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsUnknownEsophageal Cancer Stage III | Esophageal Cancer Stage IIBChina
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
National Cancer Institute (NCI)RecruitingNeoplasms | Esophageal Neoplasms | Esophagus Cancer | Esophagus Neoplasm | Neoplasms, Esophageal | Esophageal Cancer (EsC)United States
Clinical Trials on Combination of pembrolizumab and platinum containing dual drugs
-
Yongchang ZhangCompletedAdvanced Non Small Cell Lung CancerChina
-
Peking University Cancer Hospital & InstituteEnrolling by invitationLocally Advanced NSCLCChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruiting
-
The Third Xiangya Hospital of Central South UniversityCompletedHypertension | Arterial HypertensionChina
-
The First Affiliated Hospital of Nanchang UniversityActive, not recruitingHelicobacter Pylori InfectionChina
-
Taipei Medical UniversityNot yet recruitingDementia | Mild Cognitive Impairment | Older AdultIndonesia
-
University Hospital, Basel, SwitzerlandSwiss National Fund for Scientific ResearchCompletedArterial HypertensionLesotho, Switzerland, Tanzania
-
Aetion, Inc.CompletedMetastatic Lung Cancer | Non-small Cell Lung CancerUnited States
-
Ikena OncologyGilead SciencesTerminatedBreast Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Gastric Adenocarcinoma | Lung Adenocarcinoma | Advanced Solid TumorUnited States
-
Boryung Pharmaceutical Co., LtdCompletedHypertension and DyslipidemiaKorea, Republic of